IP And Trademarks 28 September 2026
Delhi HC Remands Cancer Therapy Patent Decision
India's Delhi High Court has remanded the patent refusal for Array Biopharma's cancer therapy combining a B‑Raf inhibitor with an EGFR blocker. The court ordered a fresh examination, citing procedural gaps and potential effects on drug access.
India's Delhi High Court has sent the patent case of Array Biopharma back for a fresh review after rejecting the company’s application for a B‑Raf/EGFR inhibitor cancer combo. The court highlighted procedural lapses and potential impact on drug availability.
- Case: Patent refusal for a cancer‑treatment combination
- Court action: Remand for re‑examination
- Implications: Could affect market entry and patient access
Read the full story here.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.